Discovery Therapeutics Caribe

Executive Summary

Discovery Therapeutics Caribe is a private, late-stage biotechnology company headquartered in San Juan, Puerto Rico, dedicated to developing advanced therapies for serious diseases. Its primary asset is a recombinant human Epidermal Growth Factor (rhEGF) candidate for diabetic foot ulcers (DFU), building upon the foundation of Heberprot-P, a therapy already approved in several markets outside the U.S. The company aims to bring this innovative intralesional treatment to American patients, addressing a significant unmet medical need in the DFU space. As a late-stage biotech, Discovery Therapeutics is likely engaged in regulatory discussions and clinical preparations for U.S. trials. While the company has not disclosed specific financials or trial milestones, its focus on a validated mechanism and existing approval elsewhere provides a derisked pathway. The success of the program hinges on successful U.S. clinical development and FDA alignment. The company remains privately held, with no public equity or disclosed partnerships, which limits visibility into its near-term milestones. Nonetheless, the therapeutic potential and clear regulatory pathway make it a compelling candidate in the wound healing space.

Upcoming Catalysts (preview)

• TBDFDA meeting outcomes for Phase 3 trial design75% success
• TBDInitiation of pivotal Phase 3 trial in diabetic foot ulcers60% success
• TBDPotential licensing or partnership deal for U.S. commercialization rights40% success